Key Facts:
| Effective date: | 01 January, 2027 |
| Main legal instrument: | Law of Ukraine No. 2469-IX 'On Medicinal Products |
| New authority: | Ukrainian Pharmaceutical Agency |
| Scope: | Marketing authorization, pharmacovigilance, product verification, and regulatory oversight |
| Companies affected: | Companies marketing medicines in Ukraine |
Ukraine has announced a major reform of its pharmaceutical regulatory system. This is scheduled to take effect on 01 January 2027 and includes the implementation of a new Medicines Law as well as the establishment of the Ukrainian Pharmaceutical Agency.
The reform will affect companies marketing medicines in Ukraine. It is expected to introduce a revised regulatory framework covering marketing authorization, pharmacovigilance, product verification, and regulatory oversight.
The new framework is expected to introduce broader alignment with EU regulatory concepts, including updated marketing authorization procedures, revised product information requirements, medicines verification measures, and enhanced pharmacovigilance and lifecycle management obligations.
The establishment of the Ukrainian Pharmaceutical Agency is a central element of the reform. The agency is expected to begin operating on 01 January 2027. According to information published by the Verkhovna Rada, the Ukrainian Pharmaceutical Agency is expected to become Ukraine's primary state control authority for the pharmaceutical sector.
The agency will oversee the circulation of:
Ukrainian authorities have stated that this agency is being developed in line with European regulatory principles. Its intended objectives include improving transparency, increasing predictability, and strengthening the effectiveness of regulatory oversight.
The reform is also supported by broader institutional development initiatives. These include international cooperation projects aimed at establishing an independent state control authority aligned with EU regulatory practices.
The new Medicines Law represents an important step in Ukraine’s long-term efforts to align its pharmaceutical legislation more closely with European regulatory approaches. According to Ukrainian authorities, the new law is intended to establish a more modern and robust pharmaceutical regulatory framework. It is also expected to support access to safe, effective, and high-quality medicines.
For pharmaceutical companies operating in Ukraine, the new framework may introduce changes throughout the product lifecycle. Companies may need to review their processes in the following areas:
The specific obligations for companies will depend on the secondary legislation, technical guidance, and transition arrangements issued before the reform takes effect.
The reform is being introduced as Ukraine continues to digitalize its regulatory submission processes.
The State Expert Center of the Ministry of Health of Ukraine maintains national UA Module 1 eCTD specifications and related implementation guidance for electronic Common Technical Document submissions.
Further background on the Ukrainian eCTD framework is available in our article The Ukrainian eCTD in a Nutshell.
The guidance and frequently asked questions published by the authority demonstrate Ukraine’s continued use of structured electronic dossier management and electronic submission practices.
No new technical submission requirements have been announced specifically as part of the 2027 reform package. While the reform itself does not introduce new eCTD requirements, Ukraine's broader regulatory modernization program continues to rely on electronic submissions and structured regulatory data.
However, the transition to a new regulatory framework may increase the importance of:
Companies should therefore assess whether their existing regulatory information management processes can support potential changes to Ukraine’s submission and lifecycle requirements.
Industry interest in the Ukrainian pharmaceutical reform is increasing. Industry associations and legal experts have begun organizing information sessions and webinars on the expected changes.
Topics addressed in these activities include:
The growing number of industry activities indicates that companies are beginning to assess the potential operational impact of the reform before the new framework enters into force.
Implementation details remain under development. Pharmaceutical companies marketing medicines in Ukraine should closely monitor the following publications and announcements:
1. Secondary legislation implementing the new Medicines Law
2. Technical guidance issued by the Ukrainian authorities
3. The operational structure and responsibilities of the Ukrainian Pharmaceutical Agency
4. Marketing authorization procedures and maintenance requirements
5. Pharmacovigilance and product verification requirements
6. Electronic submission specifications
7. Transition periods and implementation deadlines
These details will determine the practical impact of the reform and the actions companies must take before 01 January 2027.
Ukraine’s pharmaceutical regulatory reform is expected to bring the country’s regulatory system closer to European principles. It combines a new Medicines Law with the establishment of a new central pharmaceutical authority.
Although several implementation details remain outstanding, companies marketing medicines in Ukraine should begin monitoring the reform and assessing its potential impact on regulatory operations, product lifecycle management, pharmacovigilance, submissions, and compliance activities.